Intratect (Human Normal Immunoglobulin)

Human Normal Immunoglobulin provides a broad array of IgG antibodies that bind to pathogens, neutralize toxins, and enhance phagocytosis. It also interacts with Fc receptors on immune cells, dampening auto‑reactive activity and regulating complement pathways, thereby restoring immune balance and reducing inflammation.

The dose of Intratect is individualized. A qualified prescriber determines the amount, infusion rate, and frequency based on the patient’s weight, clinical condition, and response to therapy. Dosing guidelines are provided in the product’s prescribing information and must be followed by the treating physician.

Safety data for Intratect in pregnancy and lactation are limited. The decision to use it should be made by a healthcare professional after weighing potential benefits against unknown risks to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their physician.

To order Intratect, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling where required—and necessary import documentation.

Intratect is comparable to other IVIG preparations in providing pooled IgG antibodies for immune replacement. Differences may lie in manufacturing processes, stabilizers, and regulatory approvals. Clinicians consider factors such as infusion tolerability, specific antibody profiles, and supply chain reliability when selecting an IVIG product.

Intratect must be stored refrigerated at 2‑8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

Intratect is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate is gradually increased as tolerated, and patients are monitored for adverse reactions throughout the procedure. Premedication may be used to reduce infusion‑related symptoms.

Serious risks include anaphylactic reactions, thromboembolic events, acute renal failure, aseptic meningitis, and hemolysis. Patients should be closely observed during and after infusion, and any signs of severe allergy, clot formation, kidney dysfunction, or neurological changes require immediate medical evaluation.

Intratect is contraindicated in individuals with a known severe IgA deficiency who have anti‑IgA antibodies, as well as in patients who have experienced severe hypersensitivity to immunoglobulin products. Caution is also advised for patients with uncontrolled renal disease, active thrombotic disorders, or a history of severe infusion reactions.